Goldman Sachs Maintains Buy on Carlsmed, Lowers Price Target to $17

Benzinga Newsdesk www.benzinga.com Negative 67.5%

Neg 67.5% Neu 0% Pos 0%

Goldman Sachs analyst David Roman maintains Carlsmed (NASDAQ:CARL) with a Buy and lowers the price target from $19 to $17.